
|Articles|August 1, 2004
Aldara gets FDA nod for treatment of sBCC
St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5














